1. Home
  2. ENVB vs CISS Comparison

ENVB vs CISS Comparison

Compare ENVB & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENVB
  • CISS
  • Stock Information
  • Founded
  • ENVB 1994
  • CISS 2022
  • Country
  • ENVB United States
  • CISS Greece
  • Employees
  • ENVB N/A
  • CISS N/A
  • Industry
  • ENVB Biotechnology: Pharmaceutical Preparations
  • CISS Marine Transportation
  • Sector
  • ENVB Health Care
  • CISS Consumer Discretionary
  • Exchange
  • ENVB Nasdaq
  • CISS Nasdaq
  • Market Cap
  • ENVB 3.2M
  • CISS 3.1M
  • IPO Year
  • ENVB N/A
  • CISS N/A
  • Fundamental
  • Price
  • ENVB $1.21
  • CISS $3.60
  • Analyst Decision
  • ENVB Strong Buy
  • CISS
  • Analyst Count
  • ENVB 1
  • CISS 0
  • Target Price
  • ENVB $10.00
  • CISS N/A
  • AVG Volume (30 Days)
  • ENVB 419.0K
  • CISS 23.0K
  • Earning Date
  • ENVB 05-14-2025
  • CISS 05-15-2025
  • Dividend Yield
  • ENVB N/A
  • CISS N/A
  • EPS Growth
  • ENVB N/A
  • CISS N/A
  • EPS
  • ENVB N/A
  • CISS N/A
  • Revenue
  • ENVB N/A
  • CISS $38,174,754.00
  • Revenue This Year
  • ENVB N/A
  • CISS N/A
  • Revenue Next Year
  • ENVB N/A
  • CISS N/A
  • P/E Ratio
  • ENVB N/A
  • CISS N/A
  • Revenue Growth
  • ENVB N/A
  • CISS N/A
  • 52 Week Low
  • ENVB $1.01
  • CISS $2.85
  • 52 Week High
  • ENVB $11.97
  • CISS $29.40
  • Technical
  • Relative Strength Index (RSI)
  • ENVB 38.00
  • CISS 43.90
  • Support Level
  • ENVB $1.11
  • CISS $3.55
  • Resistance Level
  • ENVB $1.31
  • CISS $3.71
  • Average True Range (ATR)
  • ENVB 0.11
  • CISS 0.21
  • MACD
  • ENVB 0.04
  • CISS -0.00
  • Stochastic Oscillator
  • ENVB 26.33
  • CISS 9.21

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.

Share on Social Networks: